REVIEW article
Front. Cardiovasc. Med.
Sec. Heart Failure and Transplantation
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1643971
This article is part of the Research TopicTransforming Care in Heart Failure and Cardiomyopathies: Emerging Insights and TreatmentsView all 6 articles
Breaking New Ground in Heart Failure Management: Novel Therapies and Future Frontiers
Provisionally accepted
Arbab Khalid1Paulette Rodriguez1
Vasiliki Tasouli-Drakou1Abu-Bakr Ahmed2Spencer Thatcher2
Jasmine K. Dugal1*
Aditi Singh1- 1Department of Internal Medicine, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, United States
- 2Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Heart failure (HF) management is advancing in the field of cardiology, driven by the increasing availability of progressive medications. Emerging pharmacological therapies in heart failure management include SGLT-2 inhibitors, ARNI, Vericiguat, and Omecamtiv. Other novel therapies that are changing the scope of HF management include IV Iron therapy and new antifibrotic agents, such as pirfenidone and pamrevlumab. With groundbreaking approaches such as gene and stem cell-based therapies, the possibilities include gene editing and RNA-based therapies. This article contrasts novel HF therapies against previously used therapies, highlighting their mechanism of action, clinical efficiency, and relevant clinical trials. Additionally, the limitations and challenges associated with the emerging therapies will be discussed. Overall, this literature review aims to provide a comprehensive understanding of how these therapies are transforming the management of HF and related cardiomyopathies.
Keywords: Heart Failure, novel therapies, SGLT-2 inhibitors, Gene Therapy, Antifibrotic Agents Pharmacologic Advancements, ARNI, vericiguat, omecamtiv mecarbil
Received: 09 Jun 2025; Accepted: 21 Jul 2025.
Copyright: © 2025 Khalid, Rodriguez, Tasouli-Drakou, Ahmed, Thatcher, Dugal and Singh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jasmine K. Dugal, Department of Internal Medicine, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.